PRD001
Homozygous Familial Hypercholesterolemia (HoFH)
Phase 1Active (First-in-Human initiated June 2025)
Key Facts
Indication
Homozygous Familial Hypercholesterolemia (HoFH)
Phase
Phase 1
Status
Active (First-in-Human initiated June 2025)
Company
About PRD Therapeutics
A biotech startup developing the world's first selective SOAT2 inhibitor oral drugs for rare and common lipid metabolism disorders.
View full company profileAbout PRD Therapeutics
A biotech startup developing the world's first selective SOAT2 inhibitor oral drugs for rare and common lipid metabolism disorders.
View full company profileTherapeutic Areas
Other Homozygous Familial Hypercholesterolemia (HoFH) Drugs
| Drug | Company | Phase |
|---|---|---|
| Obicetrapib (TA-8995) | NewAmsterdam Pharma Company | Phase 3 |